Tarsus Pharmaceuticals, Inc. (TARS) shareholders
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (8.46%), David Kroin (8.46%) | 3,600,000 | 8.46% | 13G (passive) amendment | Mar 31, 2026 |
| Roderick Wong Joint filing with RTW Investments, LP (8.10%) | 3,424,180 | 8.10% | 13G (passive) amendment | Jun 30, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (6.40%) | 3,143,158 | 6.40% | 13G (passive) | Sep 30, 2026 |
| BlackRock, Inc. | 3,092,735 | 7.40% | 13G (passive) amendment | Mar 31, 2025 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (7.11%), David Kroin (7.11%) | 3,000,000 | 7.11% | 13G (passive) amendment | Sep 30, 2025 |
| JANUS HENDERSON GROUP Ltd. | 2,808,796 | 6.50% | 13G (passive) amendment | Jun 30, 2026 |
| Tang Capital Management, LLC Joint filing with Kevin Tang (5.90%), Tang Capital Partners, LP (5.61%) | 2,454,797 | 5.90% | 13G (passive) amendment | Mar 31, 2025 |
| Senai Asefaw, M.D Joint filing with Paradigm BioCapital Advisors LP (6.40%), Paradigm BioCapital Advisors GP LLC (6.40%) and 1 more | 2,440,445 | 6.40% | 13G (passive) amendment | Sep 30, 2024 |
| Janus Henderson Group PLC | 2,240,963 | 5.30% | 13G (passive) | Mar 31, 2026 |
| Tang Capital Partners, LP Joint filing with Tang Capital Management, LLC (6.00%), Kevin Tang (6.70%) | 2,204,797 | 6.70% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TARS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,856,137 | 8.79% | $242.71M | +303,525 | 0.00% |
| Deep Track Capital, LP | 3,666,768 | 8.36% | $230.79M | +66,768 | 3.36% |
| Rtw Investments, LP | 3,357,059 | 7.65% | $211.29M | +11,034 | 1.80% |
| Jupiter Topco LLC | 2,808,796 | 6.40% | $176.83M | New | 0.07% |
| Paradigm Biocapital Advisors LP | 2,775,649 | 6.33% | $174.70M | +213,495 | 3.27% |
| Assenagon Asset Management S.A. | 1,894,990 | 4.32% | $119.27M | +614,796 | 0.07% |
| Morgan Stanley | 1,827,082 | 4.16% | $115.00M | −117,190 | 0.01% |
| Vanguard Capital Management LLC | 1,793,064 | 4.09% | $112.86M | +32,523 | 0.00% |
| Jennison Associates LLC | 1,663,655 | 3.79% | $104.71M | −48,469 | 0.06% |
| Tang Capital Management LLC | 1,568,266 | 3.57% | $98.71M | +379,642 | 4.48% |
| Millennium Management LLC | 1,427,124 | 3.25% | $89.82M | +862,545 | 0.03% |
| Bank Of America Corp /De/ | 1,193,182 | 2.72% | $75.10M | −1,195 | 0.00% |
| Geode Capital Management, LLC | 1,105,689 | 2.52% | $69.61M | −15,402 | 0.00% |
| State Street Corp | 1,072,951 | 2.45% | $67.53M | +94,739 | 0.00% |
| Vestal Point Capital, LP | 1,050,000 | 2.39% | $66.09M | +850,000 | 1.54% |
| Invesco Ltd. | 785,808 | 1.79% | $49.46M | +43,311 | 0.00% |
| Goldman Sachs Group Inc | 742,693 | 1.69% | $46.75M | +303,067 | 0.00% |
| Frazier Life Sciences Management, L.P. | 728,644 | 1.66% | $45.86M | – | 1.00% |
| D. E. Shaw & Co., Inc. | 710,559 | 1.62% | $44.72M | −80,587 | 0.02% |
| FMR LLC | 672,949 | 1.53% | $42.36M | −60,385 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 257 | 48M | 100.0% | 40 / 104 | 84 / 33 | 10M | 4M |
| Q1 2026 | 253 | 45M | 100.0% | 48 / 88 | 82 / 36 | 7M | 4M |
| Q4 2025 | 246 | 44M | 100.0% | 52 / 84 | 85 / 23 | 5M | 6M |
| Q3 2025 | 220 | 45M | 100.0% | 37 / 67 | 92 / 22 | 4M | 6M |
| Q2 2025 | 205 | 46M | 100.0% | 44 / 87 | 50 / 30 | 8M | 5M |
| Q1 2025 | 194 | 44M | 100.0% | 36 / 67 | 71 / 34 | 8M | 4M |
| Q4 2024 | 195 | 40M | 91.7% | 58 / 65 | 55 / 22 | 7M | 10M |
| Q3 2024 | 162 | 44M | 100.0% | 40 / 55 | 44 / 25 | 10M | 4M |
| Q2 2024 | 148 | 41M | 92.4% | 26 / 67 | 41 / 34 | 7M | 11M |
| Q1 2024 | 157 | 44M | 100.0% | 47 / 60 | 32 / 6 | 13M | 4M |
| Q4 2023 | 116 | 35M | 78.7% | 28 / 48 | 22 / 17 | 8M | 4M |
| Q3 2023 | 105 | 30M | 67.9% | 25 / 49 | 13 / 12 | 9M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
240 funds held TARS in Q2 2026, 39% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TARS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,295,411 | 2.95% | $81.53M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,089,912 | 2.48% | $68.60M | 0.08% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 457,872 | 1.04% | $27.03M | 0.08% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 455,507 | 1.04% | $28.67M | 0.03% | Jun 30, 2026 |
| PGIM Jennison Small Company Fund | 408,226 | 0.93% | $25.69M | 0.74% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 386,634 | 0.88% | $24.33M | 0.16% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 346,737 | 0.79% | $21.82M | 0.38% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 342,284 | 0.78% | $21.54M | 1.84% | Jun 30, 2026 |
| ClearBridge Small Cap Growth Fund | 309,489 | 0.71% | $18.27M | 0.96% | Jul 31, 2026 |
| iShares Biotechnology ETF | 286,097 | 0.65% | $18.01M | 0.20% | Jun 30, 2026 |
| Janus Henderson Triton Fund | 283,659 | 0.65% | $17.85M | 0.30% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 228,960 | 0.52% | $13.60M | 0.01% | May 31, 2026 |
| Invesco Main Street Small Cap Fund | 207,376 | 0.47% | $13.05M | 0.49% | Jun 30, 2026 |
| Loomis Sayles Small Cap Growth Fund | 205,975 | 0.47% | $12.96M | 0.57% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 203,265 | 0.46% | $12.07M | 0.07% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bobak R. Azamian | President/CEO and Board Chair, Director | 851,412 | 1.94% | Nov 17, 2026 |
| Neera Clase | Chief Commercial Officer | 14,800 | 0.03% | Nov 5, 2026 |
| Seshadri Neervannan | Chief Operating Officer | 79,007 | 0.18% | Sep 9, 2026 |
| Elizabeth Yeu Lin | Chief Medical Officer | 16,177 | 0.04% | Sep 9, 2026 |
| Jeffrey S. Farrow | See Remarks | 56,801 | 0.13% | Jun 17, 2026 |
| Dianne C. Whitfield | Chief Human Resources Officer | 35,028 | 0.08% | Mar 19, 2026 |
| Bryan Wahl | General Counsel | 63,959 | 0.15% | Mar 19, 2026 |
| Aziz Mottiwala | Chief Commercial Officer | 61,480 | 0.14% | Mar 19, 2026 |
| David E. I. Pyott | Director | 10,958 | 0.02% | Sep 17, 2026 |
| William J. Link Phd | Director | 106,987 | 0.24% | Sep 17, 2026 |
| Wendy L. Yarno | Director | 16,956 | 0.04% | Sep 17, 2026 |
| Bhaskar Chaudhuri | Director | 11,654 | 0.03% | Jun 29, 2026 |
| Scott W. Morrison | Director | 13,654 | 0.03% | Jun 29, 2026 |
| Katherine Goodrich | Director | 2,233 | 0.01% | Jun 29, 2026 |
| Andrew D. Goldberg | Director | 19,654 | 0.04% | Jun 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bobak R. Azamian President/CEO and Board Chair, Director | Nov 13, 2026 | Sale(10b5-1 plan) | −10,000 | $80.31 | $803.10K | 817,991 |
| David E. I. Pyott Director | Sep 15, 2026 | Option exercise | +201 | – | – | 9,575 |
| Wendy L. Yarno Director | Sep 15, 2026 | Option exercise | +302 | – | – | 16,956 |
| William J. Link Phd Director | Sep 15, 2026 | Option exercise | +201 | – | – | 106,987 |
| William J. Link Phd Director | Sep 15, 2026 | Sale(10b5-1 plan) | −11,675 | $78.33 | $914.50K | 95,312 |
| William J. Link Phd Director | Sep 15, 2026 | Sale(10b5-1 plan) | −759 | $79.00 | $59.96K | 94,553 |
| William J. Link Phd Director | Sep 15, 2026 | Sale(10b5-1 plan) | −66 | $80.01 | $5.28K | 94,487 |
| Seshadri Neervannan Chief Operating Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −4,564 | $85.00 | $387.94K | 78,532 |
| Elizabeth Yeu Lin Chief Medical Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −5,386 | $90.00 | $484.74K | 2,547 |
| Elizabeth Yeu Lin Chief Medical Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −5,387 | $85.00 | $457.90K | 7,933 |
| Elizabeth Yeu Lin Chief Medical Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −1,590 | $90.00 | $143.10K | 1,590 |
| Elizabeth Yeu Lin Chief Medical Officer | Sep 4, 2026 | Sale(10b5-1 plan) | −1,590 | $85.00 | $135.15K | 3,180 |
| Bobak R. Azamian President/CEO and Board Chair, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −7,100 | $90.27 | $640.92K | 830,891 |
| Bobak R. Azamian President/CEO and Board Chair, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −2,900 | $91.27 | $264.68K | 827,991 |
| Bobak R. Azamian President/CEO and Board Chair, Director | Sep 2, 2026 | Sale(10b5-1 plan) | −10,000 | $80.06 | $800.60K | 837,991 |
| Elizabeth Yeu Lin Chief Medical Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −5,387 | $80.00 | $430.96K | 13,320 |
| Elizabeth Yeu Lin Chief Medical Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −1,590 | $80.00 | $127.20K | 4,770 |
| Elizabeth Yeu Lin Chief Medical Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −4,601 | $73.86 | $339.83K | 18,707 |
| Bobak R. Azamian President/CEO and Board Chair, Director | Jun 17, 2026 | Sale(10b5-1 plan) | −4,582 | $61.24 | $280.60K | 853,409 |
| Bobak R. Azamian President/CEO and Board Chair, Director | Jun 17, 2026 | Sale(10b5-1 plan) | −5,418 | $61.81 | $334.89K | 847,991 |
| Jeffrey S. Farrow See Remarks | Jun 16, 2026 | Sale | −14,396 | $60.95 | $877.44K | 56,801 |
| Jeffrey S. Farrow See Remarks | Jun 15, 2026 | Option exercise | +27,881 | – | – | 71,197 |
| Katherine Goodrich Director | Jun 15, 2026 | Sale(10b5-1 plan) | −2,954 | $62.08 | $183.38K | 2,233 |
| William J. Link Phd Director | Jun 15, 2026 | Sale(10b5-1 plan) | −1,928 | $62.94 | $121.35K | 106,786 |
| William J. Link Phd Director | Jun 15, 2026 | Sale(10b5-1 plan) | −10,572 | $61.97 | $655.15K | 108,714 |
| William J. Link Phd Director | Jun 12, 2026 | Option exercise | +2,954 | – | – | 119,286 |
| Bhaskar Chaudhuri Director | Jun 12, 2026 | Option exercise | +2,954 | – | – | 11,654 |
| Katherine Goodrich Director | Jun 12, 2026 | Option exercise | +2,954 | – | – | 5,187 |
| Scott W. Morrison Director | Jun 12, 2026 | Option exercise | +2,954 | – | – | 7,638 |
| Andrew D. Goldberg Director | Jun 12, 2026 | Option exercise | +2,954 | – | – | 19,654 |
| Wendy L. Yarno Director | Jun 12, 2026 | Option exercise | +2,954 | – | – | 16,654 |
| David E. I. Pyott Director | Apr 24, 2026 | Option exercise | +1,383 | – | – | 1,383 |
| Seshadri Neervannan Chief Operating Officer | Mar 20, 2026 | Sale(10b5-1 plan) | −2,989 | $66.75 | $199.52K | 82,791 |
| Jeffrey S. Farrow See Remarks | Mar 19, 2026 | Sale | −2,186 | $67.00 | $146.46K | 43,316 |
| Aziz Mottiwala Chief Commercial Officer | Mar 19, 2026 | Sale | −4,440 | $67.00 | $297.48K | 61,480 |
| Bryan Wahl General Counsel | Mar 19, 2026 | Sale | −4,231 | $67.00 | $283.48K | 63,959 |
| Dianne C. Whitfield Chief Human Resources Officer | Mar 19, 2026 | Sale | −4,174 | $67.00 | $279.66K | 35,028 |
| Elizabeth Yeu Lin Chief Medical Officer | Mar 19, 2026 | Sale | −390 | $67.00 | $26.13K | 23,308 |
| Seshadri Neervannan Chief Operating Officer | Mar 19, 2026 | Sale | −4,589 | $67.00 | $307.46K | 85,780 |
| Bobak R. Azamian President/CEO and Board Chair, Director | Mar 19, 2026 | Sale | −11,964 | $67.00 | $801.59K | 33,421 |
| Jeffrey S. Farrow See Remarks | Mar 18, 2026 | Sale | −2,133 | $68.71 | $146.56K | 45,502 |
| Aziz Mottiwala Chief Commercial Officer | Mar 18, 2026 | Sale | −4,330 | $68.71 | $297.51K | 65,920 |
| Bryan Wahl General Counsel | Mar 18, 2026 | Sale | −4,125 | $68.71 | $283.43K | 68,190 |
| Dianne C. Whitfield Chief Human Resources Officer | Mar 18, 2026 | Sale | −4,071 | $68.71 | $279.72K | 39,202 |
| Elizabeth Yeu Lin Chief Medical Officer | Mar 18, 2026 | Sale | −379 | $68.71 | $26.04K | 23,698 |
| Seshadri Neervannan Chief Operating Officer | Mar 18, 2026 | Sale | −3,610 | $68.71 | $248.04K | 90,369 |
| Bobak R. Azamian President/CEO and Board Chair, Director | Mar 18, 2026 | Sale | −11,667 | $68.71 | $801.64K | 45,385 |
| Jeffrey S. Farrow See Remarks | Mar 17, 2026 | Sale | −2,111 | $69.42 | $146.55K | 47,635 |
| Aziz Mottiwala Chief Commercial Officer | Mar 17, 2026 | Sale | −4,286 | $69.42 | $297.53K | 70,250 |
| Bryan Wahl General Counsel | Mar 17, 2026 | Sale | −4,084 | $69.42 | $283.51K | 72,315 |
| Dianne C. Whitfield Chief Human Resources Officer | Mar 17, 2026 | Sale | −4,029 | $69.42 | $279.69K | 43,273 |
| Elizabeth Yeu Lin Chief Medical Officer | Mar 17, 2026 | Sale | −375 | $69.42 | $26.03K | 24,077 |
| Seshadri Neervannan Chief Operating Officer | Mar 17, 2026 | Sale | −3,125 | $69.42 | $216.94K | 93,979 |
| Bobak R. Azamian President/CEO and Board Chair, Director | Mar 17, 2026 | Sale | −10,972 | $69.42 | $761.68K | 57,052 |
| William J. Link Phd Director | Mar 16, 2026 | Sale(10b5-1 plan) | −3,629 | $68.09 | $247.10K | 125,203 |
| William J. Link Phd Director | Mar 16, 2026 | Sale(10b5-1 plan) | −493 | $69.75 | $34.39K | 116,332 |
| William J. Link Phd Director | Mar 16, 2026 | Sale(10b5-1 plan) | −8,378 | $69.03 | $578.33K | 116,825 |
| Jeffrey S. Farrow See Remarks | Mar 15, 2026 | Option exercise | +13,042 | – | – | 49,746 |
| Bryan Wahl General Counsel | Mar 15, 2026 | Option exercise | +24,236 | – | – | 76,399 |
| Seshadri Neervannan Chief Operating Officer | Mar 15, 2026 | Option exercise | +26,287 | – | – | 97,104 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tarsus Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,875 shares on Sep 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| William J. Link Phd DIRECTOR | Sep 15, 2026 | 12,500 | $979.75K | Sep 15, 2026 | STOCK OPTION EXERCISE |
| Elizabeth Yeu Lin Member of immediate family of any of the foregoing | Sep 4, 2026 | 3,180 | $278.25K | Sep 4, 2026 | Open Market Purchase |
| Bobak R. Azamian OFFICER | Sep 4, 2026 | 10,000 | $905.59K | Sep 4, 2026 | PRIVATE PLACEMENT |
| Seshadri Neervannan Officer | Sep 4, 2026 | 4,564 | $387.94K | Sep 4, 2026 | Restricted Stock Vesting |
| Elizabeth Yeu Lin Officer | Sep 4, 2026 | 10,773 | $942.64K | Sep 4, 2026 | Open Market Purchase |
| Bobak R. Azamian OFFICER | Sep 2, 2026 | 10,000 | $800.57K | Sep 2, 2026 | PRIVATE PLACEMENT |
| Elizabeth Yeu Lin Officer | Sep 2, 2026 | 5,387 | $430.96K | Sep 2, 2026 | Open Market Purchase |
| Aziz Mottiwala Former Officer | Sep 2, 2026 | 8,000 | $654.37K | Sep 2, 2026 | Stock Option Exercise |
| Elizabeth Yeu Lin Member of immediate family of any of the foregoing | Sep 2, 2026 | 1,590 | $127.20K | Sep 2, 2026 | Open Market Purchase |
| Elizabeth Yeu Lin Officer | Sep 1, 2026 | 4,601 | $339.83K | Sep 1, 2026 | Restricted Stock Vesting |
| Aziz Mottiwala Former Officer | Sep 1, 2026 | 77,698 | $5.75M | Sep 1, 2026 | Stock Option Exercise |
| Aziz Mottiwala Former Officer | Aug 25, 2026 | 81,332 | $5.84M | Aug 25, 2026 | Stock Option Exercise |
| Aziz Mottiwala Former Officer | Aug 19, 2026 | 53,043 | $3.82M | Aug 19, 2026 | Stock Option Exercise |
| Bobak R. Azamian OFFICER | Jun 17, 2026 | 10,000 | $615.47K | Jun 17, 2026 | PRIVATE PLACEMENT |
| Jeffrey S. Farrow Officer | Jun 16, 2026 | 14,396 | $877.46K | Jun 16, 2026 | Restricted Stock Vesting |
See a number that looks wrong?